{"id":"ryz101","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"},{"rate":"null","effect":"Increased risk of genital yeast infections"},{"rate":"null","effect":"Increased risk of hypotension"}]},"_chembl":{"chemblId":"CHEMBL6068416","moleculeType":"Protein","molecularWeight":"1657.65"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, RYZ101 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as canagliflozin and empagliflozin.","oneSentence":"RYZ101 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:58.503Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Heart failure"}]},"trialDetails":[{"nctId":"NCT06590857","phase":"PHASE1, PHASE2","title":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.","status":"ACTIVE_NOT_RECRUITING","sponsor":"RayzeBio, Inc.","startDate":"2024-07-19","conditions":"Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer","enrollment":16},{"nctId":"NCT05477576","phase":"PHASE3","title":"Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","status":"RECRUITING","sponsor":"RayzeBio, Inc.","startDate":"2022-03-24","conditions":"GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease","enrollment":288},{"nctId":"NCT07150806","phase":"PHASE1, PHASE2","title":"RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma","status":"RECRUITING","sponsor":"Joshua Palmer","startDate":"2025-11-12","conditions":"Recurrent Meningioma","enrollment":30},{"nctId":"NCT05595460","phase":"PHASE1","title":"Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC","status":"RECRUITING","sponsor":"RayzeBio, Inc.","startDate":"2022-10-10","conditions":"SCLC,Extensive Stage","enrollment":49},{"nctId":"NCT06411301","phase":"PHASE1","title":"A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors","status":"WITHDRAWN","sponsor":"Jules Bordet Institute","startDate":"2024-10","conditions":"Multiple Myeloma, Refractory, Multiple Myeloma in Relapse, Multiple Myeloma Progression","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RYZ101","genericName":"RYZ101","companyName":"RayzeBio, Inc.","companyId":"rayzebio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RYZ101 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Heart failure.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}